Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1988 Mar;81(3):853–859. doi: 10.1172/JCI113394

Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.

R Pannell 1, J Black 1, V Gurewich 1
PMCID: PMC442536  PMID: 2963831

Abstract

Tissue plasminogen activator (t-PA) and/or pro-urokinase (pro-UK) induced lysis of standard 125I-fibrin clots suspended in plasma was studied. Doses were kept below the concentration at which a nonspecific effect was seen, i.e., where fibrinogenolysis and major plasminogen consumption were observed. Small amounts of t-PA potentiated clot lysis by pro-UK by attenuating the lag phase characteristic of pro-UK, and causing a much earlier transition to the rapid phase of lysis. Similar promotion of the fibrinolytic effect of pro-UK was obtained when clots were pretreated with UK or with a little plasmin (less than 1% clot lysis). Promotion by plasmin was nullified by a subsequent treatment of the clot with carboxypeptidase B, indicating that the plasmin effect was related to the exposure of carboxy terminal lysine residues on fibrin. These lysine termini, absent in undegraded fibrin, are known to be essential for the high affinity binding of plasminogen to fibrin. In contrast, clot lysis by t-PA was unaffected by plasmin pretreatment and little affected by carboxypeptidase B treatment of the fibrin substrate. Therefore, plasminogen bound to lysine termini on fibrin, although found to be essential for pro-UK, did not appear to serve as a substrate for t-PA. Selective activation of fibrin bound plasminogen has been attributed to the conformational change in Glu-plasminogen that occurs as a result of binding. The present findings suggest that this conformational change occurs when plasminogen is bound to a terminal lysine but not to an internal lysine. Plasminogen bound to the latter site on fibrin was activated by t-PA and therefore is involved in the ternary complex. This initiates lysis of the undegraded clot and exposes the plasminogen binding sites required by pro-UK. By their complementary activation of fibrin bound plasminogen, t-PA followed by pro-UK induces efficient and synergistic fibrinolysis, whereas each is relatively inefficient when used alone.

Full text

PDF
853

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Budzynski A. Z. Fibrinogen and fibrin: biochemistry and pathophysiology. Crit Rev Oncol Hematol. 1986;6(2):97–146. doi: 10.1016/s1040-8428(86)80019-1. [DOI] [PubMed] [Google Scholar]
  2. Christensen U. C-terminal lysine residues of fibrinogen fragments essential for binding to plasminogen. FEBS Lett. 1985 Mar 11;182(1):43–46. doi: 10.1016/0014-5793(85)81150-9. [DOI] [PubMed] [Google Scholar]
  3. Christensen U. The AH-site of plasminogen and two C-terminal fragments. A weak lysine-binding site preferring ligands not carrying a free carboxylate function. Biochem J. 1984 Oct 15;223(2):413–421. doi: 10.1042/bj2230413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Collen D., De Cock F., Demarsin E., Lijnen H. R., Stump D. C. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro. Thromb Haemost. 1986 Aug 20;56(1):35–39. [PubMed] [Google Scholar]
  5. Collen D. On the regulation and control of fibrinolysis. Edward Kowalski Memorial Lecture. Thromb Haemost. 1980 Jun 18;43(2):77–89. [PubMed] [Google Scholar]
  6. Collen D., Stassen J. M., Stump D. C., Verstraete M. Synergism of thrombolytic agents in vivo. Circulation. 1986 Oct;74(4):838–842. doi: 10.1161/01.cir.74.4.838. [DOI] [PubMed] [Google Scholar]
  7. Collen D., Stump D. C., Van de Werf F. Coronary thrombolysis in patients with acute myocardial infarction by intravenous infusion of synergic thrombolytic agents. Am Heart J. 1986 Nov;112(5):1083–1084. doi: 10.1016/0002-8703(86)90323-6. [DOI] [PubMed] [Google Scholar]
  8. Gurewich V., Pannell R. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity. Thromb Res. 1986 Oct 15;44(2):217–228. doi: 10.1016/0049-3848(86)90137-4. [DOI] [PubMed] [Google Scholar]
  9. Gurewich V., Pannell R., Louie S., Kelley P., Suddith R. L., Greenlee R. Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. J Clin Invest. 1984 Jun;73(6):1731–1739. doi: 10.1172/JCI111381. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Gurewich V., Pannell R. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect. Thromb Haemost. 1987 Jun 3;57(3):372–373. [PubMed] [Google Scholar]
  11. Harpel P. C., Chang T. S., Verderber E. Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem. 1985 Apr 10;260(7):4432–4440. [PubMed] [Google Scholar]
  12. Hoylaerts M., Rijken D. C., Lijnen H. R., Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem. 1982 Mar 25;257(6):2912–2919. [PubMed] [Google Scholar]
  13. Husain S. S., Gurewich V., Lipinski B. Purification and partial characterization of a single-chain high-molecular-weight form of urokinase from human urine. Arch Biochem Biophys. 1983 Jan;220(1):31–38. doi: 10.1016/0003-9861(83)90383-1. [DOI] [PubMed] [Google Scholar]
  14. Lijnen H. R., Zamarron C., Blaber M., Winkler M. E., Collen D. Activation of plasminogen by pro-urokinase. I. Mechanism. J Biol Chem. 1986 Jan 25;261(3):1253–1258. [PubMed] [Google Scholar]
  15. Nieuwenhuizen W., Vermond A., Voskuilen M., Traas D. W., Verheijen J. H. Identification of a site in fibrin(ogen) which is involved in the acceleration of plasminogen activation by tissue-type plasminogen activator. Biochim Biophys Acta. 1983 Oct 17;748(1):86–92. doi: 10.1016/0167-4838(83)90030-4. [DOI] [PubMed] [Google Scholar]
  16. Pannell R., Gurewich V. Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). Blood. 1987 Jan;69(1):22–26. [PubMed] [Google Scholar]
  17. Violand B. N., Sodetz J. M., Castellino F. J. The effect of epsilon-amino caproic acid on the gross conformation of plasminogen and plasmin. Arch Biochem Biophys. 1975 Sep;170(1):300–305. doi: 10.1016/0003-9861(75)90121-6. [DOI] [PubMed] [Google Scholar]
  18. Váradi A., Patthy L. Beta(Leu121-Lys122) segment of fibrinogen is in a region essential for plasminogen binding by fibrin fragment E. Biochemistry. 1984 Apr 24;23(9):2108–2112. doi: 10.1021/bi00304a036. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES